Recent OIG report says Medicare could have saved up to $215.8 million on at-risk payments for G0483 definitive drug tests.
Subscribe today for access to
Articles and Reports
In case you don’t feel like reading all 3,300+ pages of the Final Rule, here’s a quick briefing on the main changes you should be aware of.
Video telehealth during the early period of the COVID-19 quarantine was actually highly effective in providing accurate diagnoses, research shows.
For labs and other healthcare providers, a bill now before the Senate could mean a less labor-intensive prior authorization process.
Pathologist Rajesh C. Dash, MD, discusses the state of AI and digital pathology, as well as challenges and possible solutions.
Two lab staffing experts weigh in on current trends and what labs need to do to attract and retain talent in today’s environment.
Follow the steps in this form to help you develop and implement an effective healthcare equity plan for your lab.
Biden administration blames the decision on Congress’ failure to provide the additional funding necessary to keep the program going.
While the rule is not yet final, it’s likely that labs will have to pay more in direct CLIA compliance expenses, starting in October.
For labs, the big takeaway is how prominently molecular testing and profiling figures in so many aspects of the NCCN’s recommendations.
Most healthcare-related enforcement actions from July and August involved urine drug tests and genetic testing.
The VALID Act for FDA regulation of laboratory developed tests is working its way through the final stages of the legislative process, but not everyone is loving it.